J Rosenstock

Summary

Affiliation: Dallas Diabetes and Endocrine Center
Country: USA

Publications

  1. ncbi request reprint Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
    J Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, TX 75230, USA
    Diabetes Obes Metab 8:650-60. 2006
  2. ncbi request reprint Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Medical City Dallas Hospital, Dallas, TX
    Diabetes Care 37:2317-25. 2014
  3. ncbi request reprint Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX
    Diabetes Care 37:1815-23. 2014
  4. ncbi request reprint Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA Electronic address
    J Diabetes Complications 28:386-92. 2014
  5. pmc Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets
    J Hans DeVries
    Department of Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands
    Diabetes Care 35:1446-54. 2012
  6. pmc Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)
    Julio Rosenstock
    Corresponding author Julio Rosenstock
    Diabetes Care 36:2945-51. 2013
  7. pmc The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA
    Diabetes Care 36:498-504. 2013
  8. ncbi request reprint Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
    Postgrad Med 124:14-20. 2012
  9. ncbi request reprint Initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with early type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
    Postgrad Med 124:7-13. 2012
  10. pmc Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
    Diabetes Care 35:1232-8. 2012

Detail Information

Publications85

  1. ncbi request reprint Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
    J Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, TX 75230, USA
    Diabetes Obes Metab 8:650-60. 2006
    ....
  2. ncbi request reprint Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Medical City Dallas Hospital, Dallas, TX
    Diabetes Care 37:2317-25. 2014
    ..Harmony 6 was a randomized, open-label, active-controlled trial testing once-weekly albiglutide vs. thrice-daily prandial insulin lispro as an add-on to titrated once-daily insulin glargine...
  3. ncbi request reprint Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX
    Diabetes Care 37:1815-23. 2014
    ..We investigated the efficacy and safety of the sodium glucose cotransporter 2 inhibitor, empagliflozin, added to multiple daily injections of insulin (MDI insulin) in obese patients with type 2 diabetes mellitus (T2DM)...
  4. ncbi request reprint Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA Electronic address
    J Diabetes Complications 28:386-92. 2014
    ..To assess efficacy and safety of lixisenatide once-daily versus placebo in type 2 diabetes mellitus (T2DM) patients inadequately controlled on sulfonylurea (SU) ± metformin...
  5. pmc Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets
    J Hans DeVries
    Department of Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands
    Diabetes Care 35:1446-54. 2012
    ..We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%...
  6. pmc Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)
    Julio Rosenstock
    Corresponding author Julio Rosenstock
    Diabetes Care 36:2945-51. 2013
    ..To compare efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled with metformin...
  7. pmc The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA
    Diabetes Care 36:498-504. 2013
    ..Taspoglutide is a long-acting glucagon-like peptide 1 receptor agonist developed for treatment of type 2 diabetes. The efficacy and safety of once-weekly taspoglutide was compared with twice-daily exenatide...
  8. ncbi request reprint Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
    Postgrad Med 124:14-20. 2012
    ..To evaluate the efficacy and safety of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes...
  9. ncbi request reprint Initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with early type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
    Postgrad Med 124:7-13. 2012
    ..To evaluate initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with type 2 diabetes mellitus...
  10. pmc Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
    Diabetes Care 35:1232-8. 2012
    ..To evaluate the effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes mellitus inadequately controlled with metformin monotherapy...
  11. pmc Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA
    Diabetes Care 35:1473-8. 2012
    ..To examine the safety and efficacy of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, added on to pioglitazone in type 2 diabetes inadequately controlled on pioglitazone...
  12. pmc Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial
    Joseph C Arezzo
    Albert Einstein College of Medicine, New York, NY, USA
    BMC Neurol 8:33. 2008
    ..We evaluated the efficacy of pregabalin 600 mg/d (300 mg dosed BID) versus placebo for relieving DPN-associated neuropathic pain, and assessed its safety using objective measures of nerve conduction (NC)...
  13. ncbi request reprint Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas 75230, USA
    Curr Opin Endocrinol Diabetes Obes 14:98-107. 2007
    ..To review recent clinical trials of oral dipeptidyl peptidase-4 inhibitors and examine their role in managing type 2 diabetes mellitus...
  14. ncbi request reprint Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane, Dallas, TX 75230, USA
    Diabetes Care 30:217-23. 2007
    ..To compare the efficacy and tolerability of vildagliptin and rosiglitazone during a 24-week treatment in drug-naïve patients with type 2 diabetes...
  15. ncbi request reprint Reflecting on type 2 diabetes prevention: more questions than answers!
    J Rosenstock
    Dallas Diabetes and Endocrine Center, Medical City, Dallas, TX 75230, USA
    Diabetes Obes Metab 9:3-11. 2007
    ..These characteristics, combined with a low risk of hypoglycaemia, weight neutrality and what appears - so far - to be a relatively benign tolerability profile, make these agents intriguing candidates for preventive treatment...
  16. pmc SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
    Diabetes Care 31:2169-76. 2008
    ..The purpose of this study was to assess the glucose-lowering efficacy and safety of rimonabant monotherapy in drug-naive type 2 diabetic patients...
  17. pmc Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
    Diabetes Care 31:2177-82. 2008
    ....
  18. pmc Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
    Diabetes Care 31:1723-8. 2008
    ..The purpose of this study was to evaluate the 2-year pulmonary safety of inhaled human insulin (Exubera [EXU]) in 635 nonsmoking adults with type 2 diabetes...
  19. doi request reprint Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
    J Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
    Diabetes Obes Metab 10:376-86. 2008
    ..The aim of this study was to evaluate the safety and efficacy of dose ranges of the DPP-4 inhibitor saxagliptin (BMS-477118) in patients with T2DM...
  20. pmc A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
    J Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane C 685, Dallas, TX 75230, USA
    Diabetologia 51:408-16. 2008
    ....
  21. ncbi request reprint Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
    Diabetes Care 31:20-5. 2008
    ....
  22. doi request reprint Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes
    J Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA
    Diabetes Obes Metab 10:862-73. 2008
    ..To assess the efficacy and tolerability of early combination therapy with rosiglitazone (RSG) and glimepiride (GLIM) vs. GLIM monotherapy in patients with type 2 diabetes mellitus (T2DM)...
  23. doi request reprint Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus
    J Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas 75230, USA
    Diabetes Obes Metab 11:571-8. 2009
    ..To assess the long-term safety and the sustained glycaemic control of vildagliptin compared with rosiglitazone over 2-year treatment in drug-naïve type 2 diabetes mellitus patients...
  24. pmc Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study
    J Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane C 685, Dallas, TX, 75230, USA
    Diabetologia 52:1778-88. 2009
    ..This long-term study was designed to further characterise the retinal safety profile of insulin glargine and human neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes mellitus...
  25. doi request reprint Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes
    J Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA
    Diabet Med 28:464-9. 2011
    ..This study assessed the efficacy and safety of PF-734200 at dose rates of 20 and 30 mg/day in subjects with Type 2 diabetes mellitus inadequately controlled on metformin monotherapy...
  26. pmc Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
    Diabetes Care 33:2406-8. 2010
    ..To assess the efficacy and tolerability of alogliptin plus pioglitazone for initial combination therapy in drug-naïve type 2 diabetic patients...
  27. ncbi request reprint Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
    Endocr Pract 16:629-40. 2010
    ..To evaluate the efficacy and safety of initial combination therapy with metformin plus colesevelam in patients with early type 2 diabetes...
  28. doi request reprint Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
    Lancet 375:2244-53. 2010
    ..We aimed to assess the efficacy and safety of prandial Technosphere inhaled insulin compared with twice daily biaspart insulin...
  29. pmc Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
    Diabetes Care 33:1173-5. 2010
    ..To assess the effects of exenatide on body weight and glucose tolerance in nondiabetic obese subjects with normal or impaired glucose tolerance (IGT) or impaired fasting glucose (IFG)...
  30. doi request reprint Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Texas 75230, USA
    Diabetes Technol Ther 11:697-705. 2009
    ..New York, NY] (insulin human [recombinant DNA origin]) inhalation powder} in adults with type 2 diabetes (T2DM)...
  31. ncbi request reprint Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia
    J Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, TX 75230, USA
    Diabetes Obes Metab 11:1145-52. 2009
    ..To assess the efficacy and safety of alogliptin added to insulin in patients with type 2 diabetes inadequately controlled with insulin alone or combined with metformin...
  32. doi request reprint Redefining insulin therapy in type 2 diabetes mellitus
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, 7777 Forest Lane C 618, Dallas, Texas 75230, USA
    Postgrad Med 116:21-9. 2004
    ....
  33. ncbi request reprint Introduction
    Julio Rosenstock
    Dallas, Texas 75230, USA
    Postgrad Med 116:3. 2004
    ..This lack of appreciation may represent a missed opportunity to arrest or slow disease progression...
  34. doi request reprint Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
    J Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane, C 685, Dallas, TX 75230, USA
    Curr Med Res Opin 25:2401-11. 2009
    ..To evaluate the efficacy and safety of once-daily saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes (T2D) and inadequate glycemic control...
  35. pmc Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
    Diabetes Care 32:1880-6. 2009
    ....
  36. ncbi request reprint AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane C 685, Dallas, TX 75230, USA
    Expert Rev Med Devices 4:683-92. 2007
    ..The purpose of this article is to describe the AIR Inhaled Insulin System, provide an overview of other insulin-delivery systems and discuss future strategies for the treatment of diabetes...
  37. ncbi request reprint A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, Texas 75230, USA
    Diabetes Care 30:1480-6. 2007
    ....
  38. ncbi request reprint Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Medical City Dallas, 7777 Forest Lane, Suite C 618, Dallas, TX 75230, USA
    Diabetes Care 28:950-5. 2005
    ..We further assessed the risk for hypoglycemia in a meta-analysis of controlled trials of a similar design for insulin glargine versus once- or twice-daily NPH insulin in adults with type 2 diabetes...
  39. ncbi request reprint Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas 75230, USA
    Ann Intern Med 143:549-58. 2005
    ..Patients with type 2 diabetes who do not achieve glycemic control with oral agent therapy eventually require insulin...
  40. ncbi request reprint Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study
    J Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, TX 75230, USA
    Diabetes Obes Metab 8:49-57. 2006
    ..To compare the efficacy, safety and tolerability of adding rosiglitazone (RSG) vs. sulphonylurea (SU) dose escalation in older type 2 diabetes mellitus (T2DM) patients inadequately controlled on SU therapy...
  41. ncbi request reprint Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin
    J Rosenstock
    Dallas Diabetes and Endocrine Center, Texas 75230, USA
    Diabetes Care 24:631-6. 2001
    ..To determine the safety and efficacy of the long-acting analog insulin glargine compared with NPH insulin in patients with type 2 diabetes who were previously treated with insulin alone...
  42. ncbi request reprint Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane, C 618, Dallas, TX 75230, USA
    Diabetes Care 29:554-9. 2006
    ..To evaluate the efficacy and safety of add-on insulin glargine versus rosiglitazone in insulin-naïve patients with type 2 diabetes inadequately controlled on dual oral therapy with sulfonylurea plus metformin...
  43. ncbi request reprint Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control
    J Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, TX 75230, USA
    Diabetes Obes Metab 8:643-9. 2006
    ....
  44. ncbi request reprint Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial
    Julio Rosenstock
    Dallas Diabetes and Endo Research Center, 7777 Forest Lane, C618, Dallas, TX 75230, USA
    Pain 110:628-38. 2004
    ..Most adverse events were mild to moderate and did not result in withdrawal. Pregabalin was safe and effective in decreasing pain associated with DPN, and also improved mood, sleep disturbance, and quality of life...
  45. ncbi request reprint Repaglinide versus nateglinide monotherapy: a randomized, multicenter study
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, 7777 Forest Lane, Suite C618, Dallas, TX 75230, USA
    Diabetes Care 27:1265-70. 2004
    ..A randomized, parallel-group, open-label, multicenter 16-week clinical trial compared efficacy and safety of repaglinide monotherapy and nateglinide monotherapy in type 2 diabetic patients previously treated with diet and exercise...
  46. ncbi request reprint Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measures
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas 75230, USA
    Diabetes Technol Ther 9:80-8. 2007
    ..Cambridge, MA) Inhaled Insulin System] was designed to be easy to use. Training methods were compared in insulin-naive patients with type 2 diabetes...
  47. ncbi request reprint Management of type 2 diabetes mellitus in the elderly: special considerations
    J Rosenstock
    Dallas Diabetes and Endocrine Center, Medical City Dallas, Texas 75230, USA
    Drugs Aging 18:31-44. 2001
    ..Optimal glycaemic control should be possible for every patient if treatment is individualised; however, strict glycaemic control may not be achievable in all patients or even desirable in many elderly patients...
  48. ncbi request reprint Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group
    J Rosenstock
    Dallas Diabetes and Endocrine Center, Texas 75230, USA
    Diabetes Care 23:1137-42. 2000
    ..It recently received approval from the Food and Drug Administration. The aim of this study was to evaluate 2 formulations of insulin glargine for safety and efficacy in the treatment of patients with type 1 diabetes...
  49. ncbi request reprint Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
    J Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, TX, USA
    Diabetes Obes Metab 9:175-85. 2007
    ..The aim of this study was to compare efficacy and tolerability of initial combination therapy with vildagliptin/pioglitazone to component monotherapy...
  50. ncbi request reprint A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
    P Raskin
    University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
    Diabetes Care 24:1226-32. 2001
    ..To determine the efficacy and safety of rosiglitazone (RSG) when added to insulin in the treatment of type 2 diabetic patients who are inadequately controlled on insulin monotherapy...
  51. ncbi request reprint Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy
    J Rosenstock
    Dallas Diabetes and Endocrine Center, Texas, USA
    Int J Clin Pract 56:251-7. 2002
    ..Pioglitazone treatment also provided significant benefit with respect to plasma HDL-C and triglyceride levels. Whether these lipid changes have an impact on overall diabetic complications remains to be determined...
  52. doi request reprint Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetes
    Priscilla A Hollander
    Baylor University Medical Center, Dallas, Texas 75246, USA
    Diabetes Technol Ther 12:185-91. 2010
    ..New York, NY] [insulin human (recombinant DNA origin)] inhalation powder) in patients with type 2 diabetes inadequately controlled on combination oral antidiabetes agents (OADs)...
  53. ncbi request reprint Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study
    J Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA
    Diabetes Obes Metab 15:906-14. 2013
    ..To prospectively evaluate the efficacy and safety of alogliptin versus glipizide in elderly patients with type 2 diabetes mellitus (T2DM) over 1 year of treatment...
  54. doi request reprint Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Texas, USA
    Diabetes Technol Ther 11:S63-73. 2009
    ..Cambridge, MA] and Eli Lilly and Company [Indianapolis, IN]; AIR is a registered trademark of Alkermes, Inc.), intensifying glargine via validated titration algorithms (IG), or adding AIR insulin while intensifying glargine (AIR + IG)...
  55. ncbi request reprint Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes
    J Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA
    Diabet Med 30:1472-6. 2013
    ..To evaluate the safety of saxagliptin ± metformin over 4 years in patients with Type 2 diabetes mellitus...
  56. doi request reprint Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
    Alan Garber
    Baylor College of Medicine, Houston, TX, USA
    Lancet 373:473-81. 2009
    ..New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia. We aimed to investigate the safety and efficacy of liraglutide as monotherapy for this disorder...
  57. ncbi request reprint Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
    Diabetes Care 27:1318-23. 2004
    ....
  58. ncbi request reprint Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia
    J Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA
    Diabetes Obes Metab 15:1154-60. 2013
    ..To evaluate the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin added to metformin for 12 weeks in patients with type 2 diabetes...
  59. ncbi request reprint Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
    Diabetes Care 25:1529-33. 2002
    ....
  60. ncbi request reprint Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
    Clin Ther 28:1556-68. 2006
    ....
  61. ncbi request reprint Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
    Diabetes Care 31:30-5. 2008
    ..This study was conducted to determine the effects of vildagliptin on incretin hormone levels, islet function, and postprandial glucose control in subjects with impaired glucose tolerance (IGT)...
  62. ncbi request reprint Insulin therapy: optimizing control in type 1 and type 2 diabetes
    J Rosenstock
    University of Texas Southwestern Medical Center at Dallas, Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
    Clin Cornerstone 4:50-64. 2001
    ....
  63. pmc The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
    Diabetes Care 33:1516-22. 2010
    ..The efficacy and safety of the 11betaHSD1 inhibitor INCB13739 were assessed when added to ongoing metformin monotherapy in patients with type 2 diabetes exhibiting inadequate glycemic control (A1C 7-11%)...
  64. ncbi request reprint Basal insulin supplementation in type 2 diabetes; refining the tactics
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, 7777 Forest Lane, Dallas, TX 75230, USA
    Am J Med 116:10S-16S. 2004
    ....
  65. ncbi request reprint Counterpoint: Inpatient glucose management: a premature call to arms?
    Silvio E Inzucchi
    Dallas Diabetes and Endocrine Center, Medical City Dallas, 7777 Forest Lane, Suite C 618, Dallas, TX 75230, USA
    Diabetes Care 28:976-9. 2005
  66. ncbi request reprint The glucose and lipid effects of colesevelam as monotherapy in drug-naïve type 2 diabetes
    J Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA
    Horm Metab Res 46:348-53. 2014
    ..ClinicalTrials.gov identifier: NCT00789737. ..
  67. ncbi request reprint Inhaled insulin: a novel route for insulin delivery
    William T Cefalu
    University of Vermont College of Medicine, Burlington, VT, USA
    Expert Opin Investig Drugs 11:687-91. 2002
    ..The pharmacokinetics of inhaled insulin show a more physiological profile compared to conventional insulin; however, further studies to confirm long-term pulmonary safety and efficacy are needed...
  68. ncbi request reprint Effect of tesaglitazar, a dual PPARalpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial
    Barry J Goldstein
    Curr Med Res Opin 22:2575-90. 2006
    ..0 mg and 3.0 mg doses limits conclusions about the efficacy of these doses. The 0.5 mg and 1.0 mg tesaglitazar doses were identified for further investigation...
  69. ncbi request reprint Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen
    Joseph C Cappelleri
    Pfizer Inc, Global Research and Development, Groton, Connecticut 06340, USA
    Clin Ther 24:552-64. 2002
    ..It is unknown whether inhalation delivery of insulin improves patient satisfaction...
  70. ncbi request reprint The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
    Matthew C Riddle
    Oregon Health and Science University, Portland, Oregon 97201, USA
    Diabetes Care 26:3080-6. 2003
    ..To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA(1c)...
  71. ncbi request reprint Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy
    Richard E Pratley
    Vermont College of Medicine, Burlington, USA
    Diabetes Care 30:3017-22. 2007
    ..The purpose of this study was to evaluate the efficacy and safety of vildagliptin in elderly patients with type 2 diabetes...
  72. ncbi request reprint Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial
    Barry J Goldstein
    Department of Medicine, Jefferson Medical College of Thomas Jefferson University, 349 Jefferson Alumni Hall, 1020 Locust Street, Philadelphia, PA 19107, USA
    Curr Med Res Opin 22:2575-90. 2006
    ..The Glucose and Lipid Assessment in Diabetes (GLAD) trial examined the dose-response relationship of the dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist tesaglitazar in type 2 diabetic patients...
  73. ncbi request reprint Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!
    Julio Rosenstock
    Diabetes Care 30:2972-3. 2007
  74. pmc Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy
    Vivian A Fonseca
    Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Diabetes Care 31:1479-84. 2008
    ..This study tested the LDL cholesterol-lowering agent colesevelam HCl (colesevelam) as a potential novel treatment for improving glycemic control in patients with type 2 diabetes on sulfonylurea-based therapy...
  75. ncbi request reprint What are incretins, and how will they influence the management of type 2 diabetes?
    Lawrence Blonde
    Ochsner Diabeed Clinical Research Unit, Department of Internal Medicine, Ochsner Clinic Foundation, 1514 Jefferson Hwy, New Orleans, LA 70121, USA
    J Manag Care Pharm 12:S2-12; quiz S14-6. 2006
    ....
  76. ncbi request reprint Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial
    F Xavier Pi-Sunyer
    Obesity Research Center, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY 10025, USA
    JAMA 295:761-75. 2006
    ..Rimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese...
  77. ncbi request reprint Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    David M Kendall
    International Diabetes Center and University of Minnesota, Minmneapolis, MN, USA
    Diabetes Care 28:1083-91. 2005
    ..This study evaluated the effects of exenatide, a novel incretin mimetic, in hyperglycemic patients with type 2 diabetes unable to achieve glycemic control with metformin-sulfonylurea combination therapy...
  78. ncbi request reprint Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetes
    Julio Rosenstock
    Expert Opin Pharmacother 5:1-2; author reply 2-3. 2004
  79. ncbi request reprint Insulin glulisine provides improved glycemic control in patients with type 2 diabetes
    George Dailey
    Scripps Clinic, 10666 North Torrey Pines Rd, La Jolla, CA 92037, USA
    Diabetes Care 27:2363-8. 2004
    ..Insulin glulisine is a novel analog of human insulin designed for use as a rapid-acting insulin. This study compared the safety and efficacy of glulisine with regular human insulin (RHI) in combination with NPH insulin...
  80. ncbi request reprint Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients
    Mark L Warren
    Department of Endocrinology and Metabolism, Physicians East, PA, 1850 W Arlington Blvd, Greenville, NC 27834, USA
    Diabetes Res Clin Pract 66:23-9. 2004
    ..For some elderly type 2 diabetes patients, postprandial injection of BIAsp 30 may be an acceptable alternative to standard preprandial injection...
  81. ncbi request reprint Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine
    Satish K Garg
    Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Endocr Pract 11:11-7. 2005
    ..To compare the efficacy and safety of insulin glulisine (GLU), a new rapid-acting insulin analogue, injected 0 to 15 minutes before or immediately after meals, with regular human insulin (RHI), injected 30 to 45 minutes before meals...
  82. doi request reprint Management of prediabetes: setting the stage
    Julio Rosenstock
    Diabetes Obes Metab 9:1-2. 2007
  83. ncbi request reprint Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon
    John B Buse
    Divisions of Endocrinology and General Medicine, Diabetes Care Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7110, USA
    Endocrinol Metab Clin North Am 34:221-35. 2005
    ....
  84. ncbi request reprint Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?
    Hertzel C Gerstein
    Division of Endocrinology and Metabolism and the Population Health Research Institute, Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, ON L8N 3Z5, Canada
    Endocrinol Metab Clin North Am 34:137-54. 2005
    ..Mounting evidence suggests that insulin therapy may reduce risk for CV events while preserving beta-cell function, and several continuing long-term CV trials are testing these hypotheses explicitly...